AUNA vs KIDS

AUNA exhibits a Piotroski F-Score of 6/9, indicating stable financial health, but lacks an Altman Z-Score, limiting distress risk assessment. The stock appears undervalued with a current price of $5.66 versus a Graham Number of $12.0, suggesting defensive fair value, though growth metrics are weak with negative earnings and revenue growth. Profitability margins and ROE are positive, but high debt/equity and declining earnings raise concerns. Analysts recommend a 'buy' with a target price of $8.77, implying upside potential, but recent price volatility and deteriorating fundamentals temper bullishness.

The company exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating poor financial health and operational efficiency. While OrthoPediatrics maintains a strong gross margin (73.05%) and excellent liquidity (Current Ratio 5.55), it has failed to achieve profitability over 25 consecutive quarters. This chronic lack of earnings, combined with a bearish technical trend and significant insider selling by the CEO and COO, suggests a high-risk profile. Despite revenue growth of 17%, the inability to convert sales into net income makes the current valuation speculative.